Please login to the form below

Not currently logged in
Email:
Password:

GSK files shingles vaccine Shingrix in Europe

Blockbuster hopeful would compete with Merck & Co’s Zostavax

GlaxoSmithKline GSK 

GlaxoSmithKline has submitted its shingles vaccine Shingrix for European marketing authorisation, following on the heels of its FDA filing last month.

The UK-based pharma firm is seeking regulatory approval for the treatment of people aged 50 years and over with two intramuscular doses, given at a two-to-six month interval.

The vaccine has already been touted for blockbuster sales, after clinical data demonstrated the drug's greater efficacy in preventing shingles (herpes zoster) in older people than Merck & Co's Zostavax jab.

In the phase III clinical trial programmes ZOE-50 and ZOE-70, which evaluated the safety, efficacy and immunogenicity of Shingrix in over 50s and over 70s, the vaccine had 90% efficacy and lasted for four years.

By contrast, Zostavax - currently the only shingles vaccine on the market - has an efficacy of between 18% and 70% and is both less effective and enduring in older people.

GSK's vaccine also proved to reduce the overall incidence of postherpetic neuralgia, a form of chronic pain associated with shingles.

Dr Emmanuel Hanon, senior vice president and head of vaccines R&D at GSK, said: “GSK's shingles candidate vaccine has consistently shown high efficacy in older people in its phase III development programme.

“[This] file submission puts us a step closer to making this vaccine available to help protect more people from shingles and the complications associated with it.”

A common but serious condition, shingles that results from the reactivation of the virus that causes chicken pox and can cause lasting pain and other complications. 

The probability of developing the condition increases with age and it is that that up to one in every three people will develop shingles during their life.

Article by
Rebecca Clifford

30th November 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...